Amicus Long Term Debt vs Net Working Capital Analysis

FOLD Stock

USD 10.43 0.44 4.40%

Amicus Therapeutics financial indicator trend analysis is way more than just evaluating Amicus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amicus Therapeutics is a good investment. Please check the relationship between Amicus Therapeutics Long Term Debt and its Net Working Capital accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Long Term Debt vs Net Working Capital

Long Term Debt vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amicus Therapeutics Long Term Debt account and Net Working Capital. At this time, the significance of the direction appears to have weak relationship.

The correlation between Amicus Therapeutics' Long Term Debt and Net Working Capital is 0.39. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Amicus Therapeutics, assuming nothing else is changed. The correlation between historical values of Amicus Therapeutics' Long Term Debt and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Amicus Therapeutics are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Long Term Debt i.e., Amicus Therapeutics' Long Term Debt and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.39

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that Amicus Therapeutics has held for over one year. Long-term debt appears on Amicus Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Amicus Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Net Working Capital

Most indicators from Amicus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Issuance Of Capital Stock is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 4.6 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.19.

	2023	2024 (projected)
Extraordinary Items	90K	85.5K
Reconciled Depreciation	7.0M	6.3M

Extraordinary Items Reconciled Depreciation

Amicus Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Short Term Investments	Other Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross
Total Assets		0.85	-0.61	0.49	0.69	0.58	0.88	0.41	0.76	0.49	0.65	0.63	0.42	0.72	0.59	0.62	0.46	0.53	0.49	0.87	0.56	0.63	0.85	0.69	0.93	0.49
Total Stockholder Equity	0.85		-0.34	0.37	0.47	0.38	0.59	0.08	0.52	0.7	0.38	0.79	0.15	0.52	0.44	0.33	0.42	0.37	0.24	0.73	0.52	0.34	0.83	0.48	0.62	0.26
Retained Earnings	-0.61	-0.34		-0.03	-0.99	-0.98	-0.78	-0.84	-0.94	-0.25	-0.87	-0.29	-0.96	-0.97	-0.89	-0.97	0.27	-0.89	-0.88	-0.28	-0.8	-0.95	-0.67	-0.98	-0.61	-0.94
Other Assets	0.49	0.37	-0.03		0.1	-0.11	0.45	-0.12	0.28	0.2	0.37	0.07	-0.06	0.11	0.03	0.09	0.59	0.0	-0.11	0.62	-0.01	0.12	0.26	0.1	0.52	-0.02
Common Stock Shares Outstanding	0.69	0.47	-0.99	0.1		0.98	0.84	0.81	0.97	0.34	0.88	0.38	0.93	1.0	0.9	0.96	-0.16	0.89	0.85	0.39	0.82	0.94	0.74	1.0	0.67	0.92
Other Stockholder Equity	0.58	0.38	-0.98	-0.11	0.98		0.74	0.83	0.91	0.3	0.81	0.35	0.95	0.97	0.89	0.94	-0.31	0.89	0.88	0.24	0.83	0.92	0.69	0.97	0.55	0.93
Total Liab	0.88	0.59	-0.78	0.45	0.84	0.74		0.69	0.91	0.26	0.86	0.33	0.69	0.84	0.67	0.81	0.36	0.64	0.64	0.78	0.57	0.81	0.7	0.83	0.93	0.67
Other Current Liab	0.41	0.08	-0.84	-0.12	0.81	0.83	0.69		0.78	-0.25	0.75	-0.01	0.9	0.78	0.68	0.83	-0.18	0.67	0.74	0.22	0.55	0.82	0.37	0.81	0.52	0.78
Total Current Liabilities	0.76	0.52	-0.94	0.28	0.97	0.91	0.91	0.78		0.34	0.94	0.3	0.88	0.96	0.87	0.92	0.02	0.85	0.75	0.54	0.79	0.9	0.71	0.97	0.76	0.88
Accounts Payable	0.49	0.7	-0.25	0.2	0.34	0.3	0.26	-0.25	0.34		0.21	0.63	0.07	0.37	0.41	0.21	0.06	0.39	0.17	0.31	0.52	0.19	0.62	0.34	0.24	0.27
Cash	0.65	0.38	-0.87	0.37	0.88	0.81	0.86	0.75	0.94	0.21		0.1	0.84	0.87	0.82	0.85	0.03	0.79	0.61	0.47	0.74	0.84	0.59	0.89	0.69	0.85
Short Term Investments	0.63	0.79	-0.29	0.07	0.38	0.35	0.33	-0.01	0.3	0.63	0.1		0.1	0.42	0.34	0.35	0.0	0.27	0.47	0.32	0.43	0.38	0.86	0.36	0.4	0.15
Other Current Assets	0.42	0.15	-0.96	-0.06	0.93	0.95	0.69	0.9	0.88	0.07	0.84	0.1		0.9	0.81	0.93	-0.37	0.81	0.84	0.13	0.71	0.91	0.49	0.92	0.46	0.9
Common Stock	0.72	0.52	-0.97	0.11	1.0	0.97	0.84	0.78	0.96	0.37	0.87	0.42	0.9		0.9	0.94	-0.13	0.88	0.83	0.41	0.83	0.92	0.77	1.0	0.68	0.9
Property Plant Equipment	0.59	0.44	-0.89	0.03	0.9	0.89	0.67	0.68	0.87	0.41	0.82	0.34	0.81	0.9		0.84	-0.27	0.99	0.71	0.26	0.97	0.8	0.69	0.89	0.52	0.96
Short Long Term Debt Total	0.62	0.33	-0.97	0.09	0.96	0.94	0.81	0.83	0.92	0.21	0.85	0.35	0.93	0.94	0.84		-0.26	0.82	0.93	0.28	0.75	1.0	0.71	0.94	0.66	0.87
Other Liab	0.46	0.42	0.27	0.59	-0.16	-0.31	0.36	-0.18	0.02	0.06	0.03	0.0	-0.37	-0.13	-0.27	-0.26		-0.3	-0.41	0.82	-0.3	-0.23	0.02	-0.15	0.5	-0.32
Property Plant And Equipment Net	0.53	0.37	-0.89	0.0	0.89	0.89	0.64	0.67	0.85	0.39	0.79	0.27	0.81	0.88	0.99	0.82	-0.3		0.71	0.22	0.94	0.77	0.62	0.88	0.48	0.98
Net Debt	0.49	0.24	-0.88	-0.11	0.85	0.88	0.64	0.74	0.75	0.17	0.61	0.47	0.84	0.83	0.71	0.93	-0.41	0.71		0.11	0.63	0.94	0.68	0.82	0.53	0.74
Non Current Assets Total	0.87	0.73	-0.28	0.62	0.39	0.24	0.78	0.22	0.54	0.31	0.47	0.32	0.13	0.41	0.26	0.28	0.82	0.22	0.11		0.22	0.3	0.51	0.39	0.86	0.2
Non Currrent Assets Other	0.56	0.52	-0.8	-0.01	0.82	0.83	0.57	0.55	0.79	0.52	0.74	0.43	0.71	0.83	0.97	0.75	-0.3	0.94	0.63	0.22		0.7	0.73	0.82	0.43	0.89
Long Term Debt	0.63	0.34	-0.95	0.12	0.94	0.92	0.81	0.82	0.9	0.19	0.84	0.38	0.91	0.92	0.8	1.0	-0.23	0.77	0.94	0.3	0.7		0.73	0.92	0.68	0.83
Cash And Short Term Investments	0.85	0.83	-0.67	0.26	0.74	0.69	0.7	0.37	0.71	0.62	0.59	0.86	0.49	0.77	0.69	0.71	0.02	0.62	0.68	0.51	0.73	0.73		0.73	0.69	0.55
Common Stock Total Equity	0.69	0.48	-0.98	0.1	1.0	0.97	0.83	0.81	0.97	0.34	0.89	0.36	0.92	1.0	0.89	0.94	-0.15	0.88	0.82	0.39	0.82	0.92	0.73		0.65	0.91
Non Current Liabilities Total	0.93	0.62	-0.61	0.52	0.67	0.55	0.93	0.52	0.76	0.24	0.69	0.4	0.46	0.68	0.52	0.66	0.5	0.48	0.53	0.86	0.43	0.68	0.69	0.65		0.49
Property Plant And Equipment Gross	0.49	0.26	-0.94	-0.02	0.92	0.93	0.67	0.78	0.88	0.27	0.85	0.15	0.9	0.9	0.96	0.87	-0.32	0.98	0.74	0.2	0.89	0.83	0.55	0.91	0.49

Click cells to compare fundamentals

Amicus Therapeutics Account Relationship Matchups

Amicus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	850.2M	886.5M	905.1M	724.2M	777.9M	451.1M
Total Stockholder Equity	476.4M	286.4M	307.4M	123.0M	160.2M	168.7M
Retained Earnings	(1.8B)	(2.0B)	(2.3B)	(2.5B)	(2.7B)	(2.5B)
Other Assets	51.3M	65.4M	47.4M	42.2M	48.6M	41.8M
Common Stock Shares Outstanding	240.4M	258.9M	271.4M	289.1M	295.2M	309.9M
Liabilities And Stockholders Equity	850.2M	886.5M	905.1M	724.2M	777.9M	473.3M
Other Stockholder Equity	2.2B	2.3B	2.6B	2.7B	2.8B	3.0B
Total Liab	373.8M	600.1M	597.8M	601.1M	617.7M	648.6M
Other Current Liab	1.3M	104.2M	117.1M	110.1M	131.8M	138.4M
Total Current Liabilities	128.8M	129.7M	146.0M	139.0M	167.7M	176.1M
Accounts Payable	120.4M	17.1M	21.5M	15.4M	15.1M	21.1M
Cash	142.8M	163.2M	245.2M	148.8M	247.0M	259.3M
Short Term Investments	309.9M	320.0M	237.3M	144.8M	39.2M	37.2M
Other Current Assets	20.0M	29.7M	34.8M	40.2M	49.5M	52.0M
Common Stock	2.6M	2.7M	2.8M	2.8M	2.9M	3.1M
Property Plant Equipment	47.7M	43.9M	42.5M	30.8M	35.4M	37.2M
Short Long Term Debt Total	210.2M	441.7M	440.1M	452.1M	445.1M	467.3M
Other Liab	41.9M	35.6M	19.1M	18.5M	21.3M	20.2M
Property Plant And Equipment Net	81.0M	67.2M	63.1M	60.3M	58.0M	60.9M
Net Debt	67.4M	278.5M	194.9M	303.3M	198.1M	208.0M
Non Current Assets Total	330.1M	307.1M	308.3M	300.4M	294.8M	204.5M
Non Currrent Assets Other	28.3M	19.1M	24.4M	10.0M	15.5M	16.2M
Long Term Debt	149.5M	389.3M	389.4M	392.0M	387.9M	407.3M
Cash And Short Term Investments	452.7M	483.3M	482.5M	293.6M	286.2M	251.3M
Common Stock Total Equity	2.6M	2.7M	2.8M	2.8M	3.2M	3.4M
Non Current Liabilities Total	245.0M	470.5M	451.8M	462.1M	450.0M	243.4M
Property Plant And Equipment Gross	81.0M	67.2M	83.0M	82.6M	83.4M	87.6M
Total Current Assets	520.1M	579.5M	596.8M	423.8M	483.1M	293.7M
Accumulated Other Comprehensive Income	2.8M	8.2M	5.0M	(12.1M)	5.3M	5.6M
Net Tangible Assets	255.6M	65.6M	86.6M	(97.8M)	(112.4M)	(106.8M)
Net Receivables	33.3M	46.9M	52.7M	66.2M	87.6M	92.0M
Retained Earnings Total Equity	(1.8B)	(2.0B)	(2.3B)	(2.5B)	(2.3B)	(2.2B)
Capital Surpluse	2.2B	2.3B	2.6B	2.7B	3.1B	1.7B
Inventory	14.0M	19.6M	26.8M	23.8M	59.7M	62.7M
Deferred Long Term Liab	14.0M	12.3M	10.8M	9.6M	8.6M	8.2M
Non Current Liabilities Other	81.5M	68.9M	51.6M	60.5M	13.3M	12.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Stocks Directory Find actively traded stocks across global markets
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Commodity Directory Find actively traded commodities issued by global exchanges

Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.51)

Revenue Per Share

1.353

Quarterly Revenue Growth

0.306

Return On Assets

(0.06)

Return On Equity

(1.07)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amicus Long Term Debt vs Net Working Capital Analysis

Long Term Debt vs Net Working Capital

Long Term Debt vs Net Working Capital Correlation Analysis

Correlation Coefficient

Long Term Debt

Net Working Capital

Amicus Therapeutics fundamental ratios Correlations

Amicus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amicus Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Amicus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Common Stock Total Equity	+ 1.0	Common Stock Shares Outstanding
Common Stock Total Equity	+ 1.0	Common Stock
Long Term Debt	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 0.99	Property Plant Equipment
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding

Common Stock Shares Outstanding	- 0.99	Retained Earnings
Common Stock Total Equity	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Short Long Term Debt Total	- 0.97	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Other Current Assets	- 0.96	Retained Earnings